KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Cash (2016 - 2025)

Historic Change in Cash for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to -$4.9 million.

  • Rigel Pharmaceuticals' Change in Cash fell 13115.93% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year decrease of 14939.47%. This contributed to the annual value of $24.0 million for FY2024, which is 18773.87% up from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Change in Cash stood at -$4.9 million for Q3 2025, which was down 13115.93% from $7.7 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Change in Cash's 5-year high stood at $64.8 million during Q2 2021, with a 5-year trough of -$54.4 million in Q3 2021.
  • Over the past 5 years, Rigel Pharmaceuticals' median Change in Cash value was $2.5 million (recorded in 2022), while the average stood at $958842.1.
  • Over the last 5 years, Rigel Pharmaceuticals' Change in Cash had its largest YoY gain of 83978.99% in 2021, and its largest YoY loss of 5563061.22% in 2021.
  • Over the past 5 years, Rigel Pharmaceuticals' Change in Cash (Quarter) stood at -$11.5 million in 2021, then skyrocketed by 53.04% to -$5.4 million in 2022, then crashed by 133.55% to -$12.6 million in 2023, then surged by 140.02% to $5.1 million in 2024, then tumbled by 196.42% to -$4.9 million in 2025.
  • Its last three reported values are -$4.9 million in Q3 2025, $7.7 million for Q2 2025, and -$11.0 million during Q1 2025.